ABBOTT PARK, Ill., Sept. 28, 2020 /PRNewswire/ -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology, 8 announced today it has secured CE Mark (Conformité ...

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

MUNICH — Use of the Freestyle Libre Flash Glucose Monitoring System (Abbott Diabetes Care) significantly reduces hypoglycemia without raising HbA 1c levels in insulin-treated diabetes patients, ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

- U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement expands access of the FreeStyle Libre 2 system to Medicare patients[1] to better manage their diabetes - The FreeStyle Libre 2 ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...

- Provides broader access to FreeStyle Libre system for residents living with diabetes in Ontario and Quebec - FreeStyle Libre is the first sensor-based glucose monitoring system to be listed in any ...

The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear. Abbott announced that ...

A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional ...

ABT's strong Nutrition, Diabetes Care and EPD growth fuel momentum, but macro and currency headwinds challenge its outlook.

- The FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy[1] and optional glucose alarms directly to smartphones[2] for people ...

Freestyle-Libre-14-day_MPR-Image The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for ...